Every Form 4 that Ovid Therapeutics Inc. (OVID) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OVID and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OVID filings page.
Carter Charles Ross reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. reported that Chief Financial Officer Charles Ross received a grant of 50,000 restricted stock units (RSUs) of common stock on July 6, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of common stock at no purchase price.
The RSUs will vest in two equal annual installments beginning on July 6, 2027, subject to Ross’s continuous service through each vesting date. Following this award, Ross directly holds 94,375 shares of Ovid common stock, reflecting his equity stake in the company.
Ovid Therapeutics Inc. director Anna Greka received a grant of stock options covering 130,000 shares of common stock. The options have an exercise price of $2.26 per share and expire on June 14, 2036.
According to the grant terms, the 130,000 underlying shares vest in 36 equal monthly installments starting on July 15, 2026, contingent on her continued service with the company through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Stelios Papadopoulos received a stock-based compensation award in the form of restricted stock units. The grant covers 17,578 shares of common stock valued at $2.56 per share, replacing a $45,000 annual cash retainer. The RSUs vest 25% at grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, contingent on continued board service. After this award, he holds 217,578 common shares directly.
Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. reported that director Bart Friedman received a grant of 8,789 shares of Common Stock as a restricted stock unit (RSU) award, valued at $22,500 based on a reference price of $2.56 per share.
The RSU award was issued under Ovid’s Non-Employee Director Compensation Policy in lieu of 50% of his annual cash retainer for Board service. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026, and December 31, 2026, conditioned on his continuous service.
Fitzgerald Kevin Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Kevin Joseph Fitzgerald received a grant of 17,578 shares of common stock as a restricted stock unit (RSU) award valued at $45,000, in lieu of his annual cash retainer for board service. The RSUs were granted at $2.56 per share and vest 25% immediately, with the remaining 25% tranches scheduled on June 30, 2026, September 30, 2026, and December 31, 2026, subject to his continued service. Following this compensation award, he directly holds 17,578 shares reported in this filing.
Ovid Therapeutics Executive Chairman Jeremy M. Levin exercised a Series A warrant to acquire 47,333 shares of Common Stock at $1.40 per share. Following the exercise, he directly holds 3,735,048 shares of Common Stock.
The filing also reports 35,461 shares of Common Stock held indirectly through Divo Holdings, LLC, managed by Levin’s spouse. Levin expressly disclaims beneficial ownership of the shares held by Divo.
Ovid Therapeutics President and CEO Margaret A. Alexander reported two equity transactions. She received an employee stock option for 1,435,000 shares at an exercise price of $0.00, which will vest in 48 equal monthly installments starting on March 20, 2026, contingent on continued service.
Separately, she sold 11,656 shares of common stock at a weighted average price of $1.45 per share. According to the disclosure, this was a mandatory “sell to cover” transaction to satisfy statutory tax withholding from vesting restricted stock units, and is described as not a discretionary sale. After the sale, she directly owned 61,750 common shares and held the newly granted option for 1,435,000 shares.
Ovid Therapeutics Inc. director Stelios Papadopoulos received a grant of stock options covering 65,000 shares on February 26, 2026. These options have an exercise price of $0.00 per share, meaning they were awarded at no cost to him when granted.
The option grant will vest in full on February 26, 2027, provided he remains in continuous service with the company through that date. After this grant, he holds options on 65,000 shares directly, aligning his compensation more closely with the company’s future performance.
Fitzgerald Kevin Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Kevin Joseph Fitzgerald reported receiving an employee stock option grant covering 65,000 shares of common stock. The option was awarded on February 26, 2026 and is scheduled to vest in full on February 26, 2027, provided he remains in continuous service through that date.
Ovid Therapeutics Inc. reported that director Jeremy M. Levin received a grant of employee stock options covering 957,000 shares of Ovid common stock. These options were awarded as a form of compensation, not through an open-market purchase or sale.
According to the terms, the options will vest in 48 equal monthly installments starting on March 20, 2026. Vesting is conditioned on Levin’s continued service to the company through each vesting date, meaning he earns the right to exercise a portion of the options each month over a four-year period.
Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Bart Friedman reported receiving an equity award in the form of an employee stock option covering 65,000 shares. The option was granted at no cost on February 26, 2026 and will vest in full on February 26, 2027, provided he remains in continuous service through that date.
DUNCAN BARBARA GAYLE reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Barbara Gayle Duncan received a grant of employee stock options covering 65,000 shares on February 26, 2026. The options have a stated price of $0.0000 per share and will vest in full on February 26, 2027, subject to her continuous service through that vesting date.
Bernstein Karen reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Karen Bernstein was granted employee stock options covering 65,000 shares of Ovid common stock. The award was made on February 26, 2026 and is reported at a grant price of $0.00 per share in this filing.
According to the terms, the option will vest in full on February 26, 2027, as long as Bernstein continues to provide service to the company through that date. After vesting, the option will become exercisable for the underlying shares, subject to the company’s equity plan and any applicable restrictions.
Ovid Therapeutics Inc. chief business and financial officer Rona Jeffrey reported a mix of equity grants and a small tax-related sale. On February 26, 2026, Jeffrey received an option to purchase 408,750 shares of Common Stock and a grant of 68,125 shares of Common Stock as a restricted stock unit award, both at a price per share of $0.00. The RSUs vest in three equal annual installments beginning February 20, 2027, and the stock options vest in 48 equal monthly installments beginning March 20, 2026, conditioned on continued service.
On February 23, 2026, Jeffrey sold 8,541 shares of Common Stock at a weighted average price of $1.45 per share. According to the disclosure, this sale was a mandatory “sell to cover” transaction to satisfy statutory tax withholding obligations triggered by restricted stock unit vesting, not a discretionary sale decision.
Ovid Therapeutics Inc.'s CEO and director reported a set of insider transactions involving preferred stock, warrants, and common shares. On December 11, 2025, the reporting person purchased 71 investment units at $1,400 per unit, each unit consisting of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock.
Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares of common stock at 5 p.m. Eastern Time on December 15, 2025, resulting in 71,000 common shares after stockholder approval on December 11, 2025. Following these transactions, the reporting person directly beneficially owned 3,687,715 common shares and indirectly held 35,461 common shares through Divo Holdings, LLC, while disclaiming beneficial ownership of those indirect shares.